An improved process for preparation of niraparib phosphate

A novel process for producing Niraparib phosphate with high purity and yield addresses the limitations of existing methods, ensuring stability and suitability for pharmaceutical use.

WO2026240715A1PCT designated stage Publication Date: 2026-11-19DEVA HLDG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/TR2025/050504
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for an improved manufacturing process for Niraparib phosphate that offers enhanced stability, purity, and yield, as existing methods result in low yield and purity, making them unsuitable for large-scale production.

Method used

A novel process involving the use of tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-1-carboxylate in a polar aprotic solvent with phosphoric acid, followed by controlled stirring and crystallization, results in a 1:3 stoichiometric ratio of Niraparib phosphate, ensuring high purity and yield.

Benefits of technology

The process produces Niraparib phosphate with a purity greater than 99.81% and a yield of 96%, exhibiting stability under various environmental conditions, including high humidity and temperature, suitable for pharmaceutical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000010_0001
    Figure IMGF000010_0001
Patent Text Reader

Abstract

The present invention provides an improved process of phosphate salt for Niraparib which is chemically known as 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide. The objective of the present invention is to introduce an improved preparation method for the phosphate form of Niraparib (Compound I). Furthermore, it demonstrates that this form exhibits properties compatible with the tosylate salt of Compound I, including enhanced low hygroscopicity and good stability.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 2

[0002] DESCRIPTION

[0003] AN IMPROVED PROCESS FOR PREPARATION OF NIRAPARIB PHOSPHATE

[0004] Technical Field

[0005] The present invention provides an improved process of phosphate salt for Niraparib which is chemically known as 2-{ 4-[(3S)-piperidin-3-yl]phenyl }-2H-indazole-7-carboxamide.

[0006] Background Art

[0007] Niraparib (Compound I) is a potent poly (ADP-ribose) polymerase (PARP) inhibitor clinically approved for the treatment of ovarian, breast, and other cancers associated with BRC A mutations. It is marketed under the brand name Zejula in the European Union, the United States, and various other countries. The approved pharmaceutical formulation consists of a capsule containing 100 mg of Niraparib in the form of its monohydrated tosylate salt (Niraparib tosyl ate monohydrate). Chemically, Niraparib is designated as 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H- indazole-7-carboxamide, with its structural representation provided below.

[0008]

[0009] Compound I

[0010] Jones et al. in Journal of Medicinal Chemistry, 2009, (52), 7170-7185 and W02007113596 provided the first disclosure of a synthesis process for isolation of compound I. The pharmacological activity of Niraparib extends its therapeutic potential beyond oncology, making it a promising candidate for the treatment of various conditions. In addition to its efficacy against cancers-particularly those resistant to platinum-based chemotherapy-Niraparib shows potential in managing neurological disorders, inflammatory diseases, metabolic syndromes, cardiovascular conditions, and autoimmune diseases such as type 1 diabetes. Its ability to modulate DNA damage response mechanisms further broadens its scope of application in diverse therapeutic areas.

[0011] Niraparib is commercially available as its tosylate monohydrate salt, which was disclosed by¬ Merck Sharp & Dohme Corp, in US8436185. This patent also describes the

[0012] 3

[0013] methylbenzenesulfonate (tosylate), sulfate, benzenesulfonate, fumarate, and succinate salts of Compound I, along with their respective preparation processes. The crystalline forms of Niraparib Tosylate were first disclosed by TESARO Inc and Merck in US11091459. This application contains that monohydrate crystalline Form I is a non-hygroscopic solid exhibiting desirable solubility characteristics along with favorable physical and chemical stability. Crystalline Form II is identified as a non-stoichiometric hydrate, while anhydrous crystalline Form III is classified as a highly hygroscopic solid.

[0014] For formulation studies of solid oral dosage forms, there is a need to continuously develop new crystalline forms to enhance stability, bioavailability and manufacturability to improve the current form of a commercial API. In this context, a new crystal forms, salts and co-crystal studies has been disclosed for Compound I. The reported new salt and co-crystal forms often exhibit disadvantages, including unsuitable conditions for API production and low yields.

[0015] Niraparib Tosyl ate Form I in US8436185 has demonstrated its superiority over other forms of Compound I studied in the prior art, highlighting the need for the development of a new crystal structure. Various solid states of an active pharmaceutical ingredient offer opportunities to enhance both the drug substance and product properties. The diverse physical characteristics displayed by polymorphs impact crucial pharmaceutical parameters including storage conditions, stability, compressibility, density, and dissolution rates. Hence, identifying an appropriate crystal form of compound I is crucial for advancing drug development.

[0016] Within the field, there is a demand for polymorphs of compound I that exhibit an enhanced manufacturing process, physical and chemical properties. Consequently, the inventors of this application found it valuable to investigate a phosphate salt of compound I, aiming to enhance the characteristics of the finished medicinal product.

[0017] Niraparib phosphate was first disclosed by Zentiva in CZ32229U1, along with its other various salt forms (camsylate, naphthalene-2sulfonate, Z-(-)-malate, salicylate, hippurate, benzoate, oxalate, citrate). This application contains crystalline Form I, Form II and amorph form of phosphate salt. The inventors of CZ32229U1 patent demonstrate that, when the reaction is carried out with 1.50 equivalents of phosphoric acid (H3PO4, 85% aqueous solution), Form I exhibits a 1:2,7 stoichiometric ratio, as determined by H-NMR analysis and according to our comparative example, this process results in a very low product yield (34%) and low purity (99.31%). This process yield and purity is insufficient for a viable manufacturing process.4

[0018] Summary of the invention

[0019] The present invention introduces an improved preparation method for the phosphate form of Niraparib (Compound I). Furthermore, it demonstrates that this form exhibits properties compatible with the tosylate salt of Compound I, including enhanced low hygroscopicity, and good stability.

[0020] Technical Problem

[0021] Active pharmaceutical ingredients (APIs) are individual components that are used as a part of finished pharmaceutical drug or medicinal product, where they provide the pharmacological activity.

[0022] Research and development projects in the pharmaceutical industry mainly aim to investigate different possible salts, polymorphs and an improved process to produce these APIs.

[0023] Stability of active pharmaceutical ingredients (APIs) is the key factor in stability evaluation of finished pharmaceutical products (FPPs). On this ground, stability testing of API in FPP must be conducted.

[0024] From a storage perspective, the relative humidity and / or temperature of the environment may cause increase in impurity amount of API. Hence, stable polymorph which does not change on storage and does not require any special conditions for storage, is always preferred.

[0025] Consequently, there is continuous encouragement for the development of new polymorphic forms has a feasible production process due to their potential to improve product characteristics.

[0026] In response to demand, extensive studies have been conducted to create new polymorphic forms of compound I that exhibit beneficial properties, ideal for formulating a wide range of pharmaceutical compositions. However, there remains a demand for an alternative salt form that is compatible with Niraparib Tosylate, particularly with respect to an efficient and scalable manufacturing process.

[0027] Solution to Problem

[0028] The primary objective of this invention is to offer an enhanced and straightforward process for producing the phosphate salt (1:3 stoichiometric ratio) for Niraparib (Compound I), which meets pharmaceutical requirements such as storage, shelflife and high purity.

[0029] 5

[0030] Description of embodiments

[0031] The present invention relates to an improved method for preparing the crystalline phosphate form of Compound I using tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl (piperidine- 1 -carboxylate (Compound II) involving;

[0032] a) providing a mixture of compound II by addition of polar aprotic solvent,

[0033]

[0034] Compound II

[0035] b) then stirring the mixture at a suitable temperature for a suitable time,

[0036] c) adding phosphoric acid (H3PO4 aqueous solution) to the solution at a suitable temperature for a suitable time,

[0037] d) then stirring the mixture at a suitable temperature for a suitable time,

[0038] e) cooling the mixture to a suitable temperature and stirring for a suitable time,

[0039] f) filtering the crystals, washing with a suitable solvent, and

[0040] g) drying the crystals under a vacuum at the specified temperature.

[0041] Wherein suitable solvent in step (a) and (f) is selected from methanol, ethanol, 2-propanol, 1-propanol, 1 -butanol, 2-butanol, tert-butyl alcohol, 1 -pentanol, 2-pentanol, amyl alcohol, ethylene glycol, glycerol, acetone, butanone, 2-pentanone, 3-pentanone, methyl butyl ketone, methyl isobutyl ketone, ethyl formate, acetonitrile (ACN), tetrahydrofuran (THF), 1,4-di oxane, 2-methoxyethanol, A, A-dimethylformamide (DMF), 7V,7V-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), dimethylsulfoxide (DMSO), sulfolane, formamide, acetamide, propanamide, or mixtures thereof.

[0042] The suitable temperature used in step (b), (c), (d), (e) and (g) is selected from room temperature to reflux temperature of the solvent used.

[0043] The suitable time used to stir the mixture in step (b), (c), (d) and (e) is between 0.5 - 24 hours.

[0044] The appropriate H3PO4 amount used in step (c) is between 2.50 - 15.00 equivalents.

[0045] The suitable temperature to stir the solution in step (e) is from 10°C to 30°C.

[0046] 6

[0047] The suitable temperature to add H3PO4 in step (c) is from 15°C to 30°C.

[0048] The suitable temperature to stir the reaction mixture in step (d) is from 45°C to 90°C.

[0049] The suitable temperature to dry the product in step (g) is from 30°C to 70°C.

[0050] The improved method is simple, repeatable, cost-effective and suitable for industrial scale manufacturing.

[0051] The purity of the active ingredient significantly influences its efficacy and other crucial properties essential in pharmaceutical processing. For instance, diminished pourability or flowability of the crystalline form can impair its ability to be compressed into tablets, potentially affecting its overall effectiveness.

[0052] The process described in the present invention produces crystalline Form I in a 1:3 stoichiometric ratio (Compound I: H3PO4), which differs from the Form I disclosed in CZ32229U1. This process ensures high purity and high yield, producing the desired product with a purity greater than 99.81% by area percentage in HPLC and a yield of 96% at the pilot production scale.

[0053] Stability is a critical factor in drug development. It refers to the ability of a pharmaceutical product within a designated container or closure system to maintain its chemical, physical, microbiological, therapeutic, and toxicological properties within specified limits. This endurance ensures the product's quality attributes such as identity, purity, and strength are retained until the drug's expiration.

[0054] Absolutely, the crystalline stability of the API plays a pivotal role in meeting the requirements for a qualified pharmaceutical product. Utilizing stable polymorphs of the API in pharmaceutical formulations is essential to ensure the stability and quality of the final product.

[0055] For this aspect, crystalline stability of crystalline Form I as Niraparib triphosphate (NTP) was investigated under the condition 25 °C, 60% relative humidity (RH) for 6 months after preparation.

[0056] The crystalline stability referred to here, is the stability of a polymorphic form of API with respect to polymorph transformations, hydration or dehydration, salt disproportionation, crystallization, or amorphization through time under the condition 25 °C, 60% RH for 6 months after preparation.

[0057] The crystalline stability of NTP Form I is investigated and determined by X-ray powder diffraction method. Results show that any polymorphic transformation to another crystal form7

[0058] or any degradation in crystalline NTP Form I did not occur. Crystalline NTP Form I shows crystalline stability under 25 °C, 60% RH for 6 months. X-ray diffractogram of crystalline NTP Form I kept under the conditions at 25 °C, 60% RH for 6 months is given in Fig. 6 clearly shows that 2-theta values of characteristic peaks did not change when exposed to accelerated stability conditions.

[0059] The chemical stability of crystalline NTP Form I is also important and its stability in finished product at room-temperature storage can be predicted from shorter-term storage under accelerated conditions of high temperature and humidity.

[0060] In the present invention, samples of obtained crystalline NTP Form I are stored for 6 months in stability chambers under following condition of 25 °C 60% to test chemical stability. The chemical stability of the samples was determined by HPLC method and appearance solution test according to reference solution.

[0061] Table 1 shows the stability results of NTP Form I prepared according to the present invention in comparison to Niraparib Tosylate (NTs) Form I prepared according to US8436185. NTP Form I and NTs Form I were kept at 25°C and 60% relative humidity conditions for 6 months. At 25 °C and 60 % RH condition, initial total impurity amounts were 0.19% for NTP Form I and 0.26% for NTs Form I. The total impurity amounts at the end of 6 months were 0.22% for NTP Form I and 0.28% for NTs Form I. The total impurity levels indicate that both forms exhibit similar stability. Test of appearance and appearance of solution is stable both forms during 6 month storage condition.

[0062] Table 1. Niraparib stability test results of NTP versus NTs

[0063]

[0064] *Packed samples were kept at 25 °C and 60% relative humidity

[0065] **Prepared according to US8436185 patent

[0066] In addition to examining relative humidity conditions, forced degradation studies were conducted to assess the crystalline stability of NTP Form I. Forced degradation tests are studies8

[0067] used to assess the stability of active pharmaceutical ingredients (APIs) and their formulations. These tests are performed submitting the API under extreme conditions in order to know the main degradation products in a short period.

[0068] Table 2 shows the stability results of NTP Form I prepared according to the present invention in comparison to NTs Form I prepared according to US8436185. NTP Form I and NTs Form I were kept at 40°C, 60°C and 80°C for 15 days, day light and UV light for 15 days. The initial total impurity amounts were 0.19% for NTP Form I and 0.26% for NTs Form I. Thermal decomposition was detected at temperatures of 80°C. The total impurity amounts for the thermal degradation results were 0.23% for Form NTP Form I and 0.27% for NTs Form I. The total impurity amounts for the day light results were 0.23% for NTP Form I. The total impurity amounts for the UV-light results were 0.21% for NTP Form I. No specific degradation was observed for NTs Form I when exposed to daylight and UV light. The total impurity amounts showed that NTs Form I is slightly more stable than NTP Form I.

[0069] Table 2. Niraparib forced degradation results of NRP Form I versus NTs Form I

[0070]

[0071] *Prepared according to US8436185 patent

[0072] Ensuring the stability of APIs and their preparations under accelerated and rigorous conditions holds the utmost significance in pharmaceuticals. Throughout storage, transportation, and production, these substances may be exposed to varying temperatures and humidity levels due to seasonal and regional climate disparities and weather fluctuations. Crystalline NTP Form I9

[0073] bulk drugs and preparations exhibit excellent stability, even under harsh environmental conditions, similar to commercial NTs Form I. This resilience proves advantageous in mitigating the effects of deviations from ideal storage conditions on the drug's quality as specified on its label.

[0074] Brief description of the drawings:

[0075] Figure 1 shows the X-Ray Powder Diffraction (XRPD) pattern of NTP Form I

[0076] Figure 2 shows the Differential Scanning Calorimetry (DSC) thermogram of NTP Form I

[0077] Figure 3 shows the Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectra of NTP Form I

[0078] Figure 4 shows the 'H-NMR spectrum of NTP Form I

[0079] Figure 5 shows the °C-NMR spectrum of NTP Form I

[0080] Figure 6 shows the X-Ray Powder Diffraction (XRPD) pattern of NTP Form I (25 °C, 60% RH for 6 months)

[0081] Instrumental parameters:

[0082] NMR:

[0083] 'H and13C NMR spectra were recorded on a JEOL 400 MHz NMR spectrometer. Chemical shifts 5 are reported in parts per million (ppm) relative to the residual protons in the NMR solvent (DMSO-tZ5: 52.5 and carbon resonance of the solvent (DMSO-tZ5: 540.00; CDCh: 7.26 and carbon resonance of the solvent CDCh: 77.00). NMR peak multiplicities were given as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, quint = quintet, br = broad, C, CH, CH2, CH3.

[0084] DSC:

[0085] Samples were measured on a Shimadzu DSC-60 Differential Scanning Calorimetry. The measurement conditions were as following:

[0086] Initial temperature: 30 °C

[0087] Final temperature: 350 °C

[0088] Heating rate: 5 °C / min

[0089] Cell Aluminum

[0090] Atmosphere Nitrogen

[0091] 10

[0092] FTIR:

[0093] Samples were measured as neat by ATR (Attenuated Total Reflectance) on Shimadzu FTIR Spectrometer IR Prestige-21 (Shimadzu Corporation, Kyoto, Japan) in the range of 600 - 4000 cm-1with 20 scans and 4 cm-1resolution.

[0094] HPLC for the reaction conversion and purity:

[0095] Equipment: Shimadzu LC-2030 Plus system equipped with an SPD-40 V detector

[0096] Column: Waters HSS T3 150 x 4.6 mm, 3,5pm.

[0097] Column temperature: 40 °C

[0098] Sample temperature: 5 °C

[0099] Injection volume: 20 pL

[0100] Flow rate: 1.0 mL / min.

[0101] Elution: Gradient

[0102] Gradient Program

[0103] Mobile Phase: A: 10 mM KH2PO4pH: 5.2, B: ACN; Eluent: %80 MeOH

[0104]

[0105] PXRD Method of Analysis:

[0106] XRPD samples were analyzed on a Shimadzu 6100 X-Ray Diffractometer. The measurement conditions were as following:

[0107] Radiation: CuKal (1.5406 A)

[0108] Kai ratio: 50%

[0109] Voltage: 40.0 kV

[0110] 11

[0111] Current: 30.0 mA

[0112] Auto slit: not used

[0113] Divergence slit: 1.0°

[0114] Scatter slit: 1.0°

[0115] Receiving slit: 0.30 mm with a Graphite monochromator

[0116] Drive axis: Theta-2Theta

[0117] Scan range: 2.00 -45.00°

[0118] Scan mode: Continuous scan

[0119] Scan speed: 2.0° / min

[0120] Sampling pitch: 0.02°

[0121] Preset time: 0.60 s

[0122] The following examples are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention.

[0123] EXAMPLES

[0124] Example-1: Comparative experiment

[0125] This process was carried out using the same equivalents, temperature, and reaction time as described in Example 18 of CZ32229U1, scaled to 5 grams. In 250 mL three-neck flask equipped with a reflux condenser, a solution of tert-butyl (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidine-l-carboxylate (Compound II, 5,0 g, 0.012 mol, 1.00 eq) in methyl isobutyl ketonu (MIK, 100 mL) was treated with dropwise addition of phosphoric acid (1.23 mL, 0.018 mol, 1.50 eq, 85% aqueous solution) at room temperature. The resulting mixture was heated to 70°C and stirred for 18 hours. The reaction mixture was allowed to return to ambient levels. The precipitated reaction mixture was filtered and washed with EtOAc: MeOH (40: 10 mL). The resulting white-off solid underwent vacuum drying at 40°C for 10 hours, Niraparib phosphate Form I (2.5 g, 34%, HPLC purity: 99.31%).

[0126] EXAMPLE-2: Preparation of NTP Form I using Compound II

[0127]

[0128] Compound II Niraparib Tri-Phosphate

[0129] 12

[0130] In a reactor equipped with a dropping funnel and a reflux condenser, a solution of tert-butyl (3 S)-3 - { 4- [7-(aminocarb onyl)-2H-indazol-2-yl] phenyl } piperidine- 1 -carboxyl ate (Compound II, 126.15 g, 0.3 mol, 1.00 eq) in a mixture of acetone and ACN (1.35 L:0.15 L) was treated with dropwise addition of phosphoric acid (0.194 L, 3.3 mol, 11.00 eq, 85% aqueous solution) while maintaining the temperature between 20°C and 30°C. The resulting mixture was heated to 60°C and stirred for 20 hours. Once the reaction was completed, the temperature was allowed to return to ambient levels. The precipitated reaction mixture was filtered and washed with acetone (3 x 150 mL). The resulting white solid underwent vacuum drying at 40°C for 10 hours, Niraparib triphosphate (NTP) Form I (177.0 g, 96%). HPLC purity: 99.81%, KF(%): 0.87. The UHPLC (CAD and DAD detectors) and NMR results indicate that the sample contains 48% H3PO4, confirming that Niraparib phosphate exhibits a 1:3 stoichiometric ratio.1H NMR (400 MHz, DMSO-d6) 5 (ppm) = 9.30 (s, 1H), 9.90 - 8.45 (br, 9H), 8.56 (d, J= 2.9 Hz, 1H), 8.15 -8.10 (m, 2H), 8.08 - 7.99 (m, 2H), 7.90 (d, J= 2.9 Hz, 1H), 7.58 - 7.52 (m, 2H), 7.27 (dd, J= 8.4, 7.0 Hz, 1H), 3.32 (dd, J= 15.7, 11.0 Hz, 2H), 3.16 - 3.01 (m, 2H), 2.90 (td, J= 12.4, 3.5 Hz, 1H), 2.01 - 1.68 (m, 4H).13C NMR (100 MHz, DMSO-d6) 5 (ppm) = 166.02 (C), 146.58 (C), 142.81 (C), 138.85 (C), 130.26 (CH), 129.03 (CH), 125.86 (CH), 123.94 (CH), 123.92 (C), 122.44 (CH), 121.97 (C), 121.43 (CH), 48.27 (CH2), 43.33 (CH2), 39.25 (CH), 29.91 (CH2), 22.74 (CH2).

Claims

CLAIMS1. A process for the improved preparation of Niraparib Phosphate Form I including the following steps:X H3PO4Niraparib Phosphatea) providing a mixture of compound II by addition of polar aprotic solvent,Compound IIb) then stirring the mixture at a suitable temperature for a suitable time,c) adding phosphoric acid (H3PO4 aqueous solution) to the solution at a suitable temperature for a suitable time,d) then stirring the mixture at a suitable temperature for a suitable time,e) cooling the mixture to a suitable temperature and stirring for a suitable time, f) filtering the crystals, washing with a suitable solvent, andg) drying the crystals under a vacuum at the specified temperature.

2. The process according to claim 1, wherein the suitable solvent in step a) and f) is selected from methanol, ethanol, 2-propanol, 1 -propanol, 1 -butanol, 2-butanol, tert-butyl alcohol, 1- pentanol, 2-pentanol, amyl alcohol, ethylene glycol, glycerol, acetone, butanone, 2- pentanone, 3 -pentanone, methyl butyl ketone, methyl isobutyl ketone, ethyl formate, acetonitrile (ACN), tetrahydrofuran (THF), 1,4-di oxane, 2-methoxy ethanol, N, N- dimethylformamide (DMF), A'A -di methyl acetamide (DMAc), A-methylpyrrolidone(NMP), dimethylsulfoxide (DMSO), sulfolane, formamide, acetamide, propanamide, or mixtures thereof.

3. The process according to claim 1, wherein the suitable temperature used in step b), c), d), e) and g) is selected from room temperature to reflux temperature of the solvent used.

4. The process according to claim 1, wherein the suitable time used to stir the mixture in step b), c), d) and e) is between 0.5 - 24 hours.

5. The process according to claim 1, wherein the appropriate H3PO4 amount used in step c) is between 2.75 - 15.00 equivalents.

6. The process according to claim 1, wherein the suitable temperature to stir the solution in step e) is from 10°C to 30°C.

7. The process according to claim 1, wherein the suitable temperature to add H3PO4 in step c) is from 15°C to 30°C.

8. The process according to claim 1, wherein the suitable temperature to stir the reaction mixture in step d) is from 45°C to 90°C.

9. The process according to claim 1, wherein the suitable temperature to dry the product in step g) is from 30°C to 70°C.

10. The process according to claim 1, wherein x is between 2.8 and 3.2.

11. The process according to claim 10, wherein x is 3.3 H3PO4Niraparib Tri-Phosphate